ArticleJournal of gastrointestinal cancer2026
Clinicopathologic Characteristics, Treatments, and Survival Outcomes of Early-onset Compared to Later-onset Colorectal Mucinous Adenocarcinomas: A Population-based SEER Analysis.
Article in Journal of gastrointestinal cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundColorectal mucinous adenocarcinoma (CMA) is a unique subtype of adenocarcinoma. This study aimed to compare characteristics, treatments, and survival outcomes of early-onset and later-onset CMA.
methodsThis investigation was a retrospective cohort study from the National Cancer Institute's SEER Research Data database from 2000 to 2022 on patients with CMA. Patients aged < 50 years (early-onset) and patients aged ≥ 50 years (later-onset) were compared regarding disease characteristics, treatments, and survival. The main outcome measures were 5-year overall survival (OS) and cancer-specific survival (CSS).
resultsThe study included 55,853 patients; 10.4% of them presented with early-onset disease. Early-onset CMA more often affected males, Blacks, and Hispanics, and was more advanced and more often associated with liver metastases. Early-onset CMA was associated with higher 5-year OS (57.7% vs. 47.5%, p < 0.001) and CSS (58.4% vs. 45.4%, p < 0.001). In multivariable Cox proportional hazard analysis excluding postdiagnosis treatment variables, later-onset CMA was associated with higher all-cause mortality (HR: 1.69, 95% CI 1.53-1.87, p < 0.001) and cancer-specific mortality (HR: 1.45, 95% CI 1.30-1.61, p < 0.001) compared to early-onset disease. In a sensitivity analysis adjusting for treatment variables, these associations persisted, although they were attenuated for both OS (HR: 1.56, 95% CI 1.41-1.72, p < 0.001) and CSS (HR: 1.34, 95% CI 1.20-1.49, p < 0.001).
conclusionsEarly-onset CMA presented with different demographic and disease characteristics and treatment patterns than later-onset disease. Survival of early-onset CMA was higher than later-onset CMA.
Indexed as
Identifiers
42665769What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.